t-Butyl 1-(Hydroxymethyl)cyclopentanecarboxylate | 137613-90-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 英文名称: t-Butyl 1-(Hydroxymethyl)cyclopentanecarboxylate
• 英文别名: 1,1-dimethylethyl 1-(hydroxymethyl)cyclopentanecarboxylate；tert-butyl 1-(hydroxymethyl)cyclopentanecarboxylate；1-(hydroxymethyl)cyclopentanecarboxylic acid t-butyl ester；t-Butyl 1-hydroxymethylcyclopentanecarboxylate；Tert-butyl 1-(hydroxymethyl)cyclopentane-1-carboxylate
• CAS: 137613-90-2
• 化学式: C₁₁H₂₀O₃
• 分子量: 200.278
• InChiKey: WERJMFAMAFYNBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  t-Butyl 1-(Hydroxymethyl)cyclopentanecarboxylate 在 草酰氯 、 二甲基亚砜 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.75h， 以72%的产率得到tert-butyl 1-formylcyclopentanecarboxylate
  参考文献：
  名称：

  CYCLOPROPYLAMINES AS LSD1 INHIBITORS

  摘要：

  本发明涉及环丙胺衍生物，其为LSD1抑制剂，可用于治疗癌症等疾病。

  公开号：

  US20150225401A1
• 作为产物：
  描述：

  环戊酸 在 硫酸 、 lithium diisopropyl amide 作用下， 以 甲苯 为溶剂， 生成 t-Butyl 1-(Hydroxymethyl)cyclopentanecarboxylate
  参考文献：
  名称：

  用于中枢和周围疼痛治疗的新型口服活性双脑啡肽抑制剂（DENKIs）

  摘要：

  保护脑啡肽是响应伤害性刺激而释放的内源性阿片肽，是缓解急性和神经性疼痛的一种创新方法。这是通过抑制两个膜结合的锌金属肽酶，中性溶酶（NEP，EC 3.4.24.11）和氨基肽酶N（APN，EC 3.4.11.2）来抑制它们的酶促降解而实现的。已经设计出两种酶的选择性和有效抑制剂，称为脑啡肽酶，它们可以显着增加脑啡肽的细胞外浓度和半衰期，从而诱导有效的抗伤害感受作用。先前已经开发了几种双脑啡肽酶抑制剂（DENKIs）的化学家族，但缺乏口服活性。我们在这里报告新前药的设计和合成，衍生自将NEP和APN抑制剂通过具有侧链的二硫键结合的NEP和APN抑制剂共同改善口服生物利用度。在针对中枢和/或外周阿片样物质系统的各种疼痛动物模型中评估了它们的药理特性。考虑到它在急性和神经性疼痛中的功效，这些新的DENKI之一，选择19 - IIIa进行临床开发。

  DOI：

  10.1021/jm500602h

文献信息

• NOVEL AMINO ACID DERIVATIVES, METHOD FOR PREPARING SAME, AND THERAPEUTIC USE THEREOF
  申请人：Fournie-Zaluski Marie-Claude

  公开号：US20110071218A1

  公开（公告）日：2011-03-24

  The disclosure relates to novel compounds of the formula (I) R 1 NH—CH(R 2 )CH 2 —S—S—CH 2 —C(R 3 )(R 4 )—CONH—C(R 5 )(R 6 )—COOR 7 , in which R 1 is a (acyloxy)alkyl carbamate-C(O)—O—C(R 8 )(R 9 )—OC(O)—R 10 group; R 2 is a hydrocarbon chain, a methylene radical substituted by a heterocycle, R 4 is a hydrogen atom and R 3 is a phenyl or benzyl radical, a heteroaryl, a methylene group substituted by a heterocycle or R 3 and R 4 form together a saturated cycle; R 5 and R 6 are hydrogen, a hydrocarbon chain, a phenyl or benzyl radical or R 5 and R 6 form together a saturated cycle; R 7 is hydrogen, a phenyl or benzyl radical, a group of the formula CR 12 (R 13 )C(O)OR 14 or OCR 12 (R 13 )OC(O)R 14 or OCR 12 (R 13 )OC(O)OR 14 . The disclosure also relates to the use of these compounds as a drug, and to a pharmaceutical composition containing said compounds and a pharmaceutically acceptable carrier. The disclosure further relates to the combined use of at least one cannabinoid derivative and/or morphine or one derivative thereof and/or Gaba derivatives for enhancing the analgesic and anti-depressive effect of the compounds of the formula (I).

  该披露涉及到式(I)的新化合物R1NH—CH(R2)CH2—S—S—CH2—C(R3)(R4)—CONH—C(R5)(R6)—COOR7，其中R1是(酰氧基)烷基碳酸酯-C(O)—O—C(R8)(R9)—OC(O)—R10基团；R2是一个碳氢链，一个被杂环取代的亚甲基基团，R4是一个氢原子，R3是一个苯基或苄基基团，一个杂环基团，一个被杂环取代的亚甲基基团或R3和R4一起形成一个饱和环；R5和R6是氢，一个碳氢链，一个苯基或苄基基团，或R5和R6一起形成一个饱和环；R7是氢，一个苯基或苄基基团，一个式CR12(R13)C(O)OR14或OCR12(R13)OC(O)R14或OCR12(R13)OC(O)OR14的基团。该披露还涉及将这些化合物用作药物，以及含有所述化合物和药学上可接受的载体的药物组合物。该披露还涉及至少一种大麻素衍生物和/或吗啡或其衍生物和/或Gaba衍生物的联合使用，以增强式(I)的化合物的镇痛和抗抑郁效果。
• AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN
  申请人：Roques Bernard

  公开号：US20110124601A1

  公开（公告）日：2011-05-26

  The present invention relates to a compound of the following general formula (I): R 1 —NH—CH(R 2 )—P(═O)(OR 3 )—CH 2 —C(R 4 )(R 5 )—CONH—CH(R 6 )—COOR 7 (I) or a pharmaceutically acceptable salt of the latter, an isomer or a mixture of isomers in any proportions, especially a mixture of enantiomers, and in particular a racemic mixture, for which R 1 represents a —C(═O)—O—C(R 8 )(R 9 )—OC(═O)—R 10 group; R 2 represents an optionally substituted hydrocarbon-based chain, an aryl or heteroaryl group or a methylene group substituted by a heterocycle; R 3 represents a hydrogen atom or a —C(R 12 )(R 13 )—OC(═O)—R 14 group; R 4 and R 5 form, together with the carbon that bears them, a saturated hydrocarbon-based ring or an optionally substituted piperidine ring or R 4 represents a hydrogen atom and R 5 represents a phenyl or a benzyl that is optionally substituted, a heteroaromatic ring or a methylene group substituted by a heterocycle; R 6 represents an optionally substituted hydrocarbon-based chain or a phenyl or a benzyl that is optionally substituted; and R 7 represents a hydrogen atom or a benzyl, alkyl, heteroaryl, alkylheteroaryl, —CHMe—COOR 18 , —CHR 19 —OC(═O)OR 20 and —CHR 19 —OC(═O)OR 20 group. The present invention also relates to the use of these compounds as a medicinal product, and in particular for the treatment of pain, more advantageously neuropathic and neuroinflammatory pain, to their method of synthesis and also to the compositions containing them.

  本发明涉及以下通式（I）的化合物：R1—NH—CH（R2）—P（═O）（OR3）—CH2—C（R4）（R5）—CONH—CH（R6）—COOR7或其药学上可接受的盐、异构体或任意比例的异构体混合物，特别是对映体混合物，尤其是外消旋混合物，其中R1代表—C（═O）—O—C（R8）（R9）—OC（═O）—R10基团；R2代表可选取代的碳氢链、芳基或杂环芳基基团或被杂环取代的亚甲基基团；R3代表氢原子或—C（R12）（R13）—OC（═O）—R14基团；R4和R5与承载它们的碳原子一起形成饱和碳氢基环或可选取代的哌啶环或R4代表氢原子，R5代表可选取代的苯基或苄基、杂环芳基环或被杂环取代的亚甲基基团；R6代表可选取代的碳氢链或可选取代的苯基或苄基；R7代表氢原子或苄基、烷基、杂环芳基、烷基杂环芳基、—CHMe—COOR18、—CHR19—OC（═O）OR20和—CHR19—OC（═O）OR20基团。本发明还涉及这些化合物作为药物的用途，特别是用于疼痛治疗，更有利的是神经病理性和神经炎性疼痛的治疗，以及它们的合成方法和含有它们的组合物。
• Mercaptocycloacyl aminoacid endopeptidase inhibitors
  申请人：Schering Corporation

  公开号：US05407960A1

  公开（公告）日：1995-04-18

  Mercaptocycloacyl aminoacid inhibitors of endopeptidase of the formula ##STR1## or a pharmaceutically acceptable salt thereof, alone or in combination with an ACE inhibitor or an ANF, in the treatment of cardiovascular disorders such as hypertension, congestive heart failure, edema and renal insufficiency, and treatment of nephrotoxicity pain conditions, and pharmaceutical compositions containing said compounds are disclosed.

  公开了公式##STR1##的内肽酶巯基环酰氨基酸抑制剂或其药学上可接受的盐，单独或与ACE抑制剂或ANF结合，用于治疗高血压、充血性心力衰竭、水肿和肾功能不全等心血管疾病，以及治疗肾毒性疼痛症状，并且公开了含有这些化合物的药物组合物。
• Aminophosphinic derivatives that can be used in the treatment of pain
  申请人：PHARMALEADS

  公开号：US10131681B2

  公开（公告）日：2018-11-20

  The present invention relates to a compound of the following general formula (I): R1—NH—CH(R2)—P(═O)(OR3)—CH2—C(R4)(R5)—CONH—CH(R6)—COOR7 (I) or a pharmaceutically acceptable salt of the latter, an isomer or a mixture of isomers in any proportions, especially a mixture of enantiomers, and in particular a racemic mixture, for which R1 represents a —C(═O)—O—C(R8)(R9)—OC(═O)—R10 group; R2 represents an optionally substituted hydrocarbon-based chain, an aryl or heteroaryl group or a methylene group substituted by a heterocycle; R3 represents a hydrogen atom or a —C(R12)(R13)—OC(═O)—R14 group; R4 and R5 form, together with the carbon that bears them, a saturated hydrocarbon-based ring or an optionally substituted piperidine ring or R4 represents a hydrogen atom and R5 represents a phenyl or a benzyl that is optionally substituted, a heteroaromatic ring or a methylene group substituted by a heterocycle; R6 represents an optionally substituted hydrocarbon-based chain or a phenyl or a benzyl that is optionally substituted; and R7 represents a hydrogen atom or a benzyl, alkyl, heteroaryl, alkylheteroaryl, —CHMe-COOR18, —CHR19—OC(═O)R20 and —CHR19—OC(═O)OR20 group. The present invention also relates to the use of these compounds as a medicinal product, and in particular for the treatment of pain, more advantageously neuropathic and neuroinflammatory pain, to their method of synthesis and also to the compositions containing them.

  本发明涉及以下通式(I)的化合物：R1-NH-CH(R2)-P(═O)(OR3)-CH2-C(R4)(R5)-CONH-CH(R6)-COOR7(I)或后者的药学上可接受的盐、异构体或任何比例的异构体混合物，特别是对映体混合物，尤其是外消旋混合物，其中R1代表-C(═O)-O-C(R8)(R9)-OC(═O)-R10基团；R2 代表任选取代的烃基链、芳基或杂芳基或被杂环取代的亚甲基； R3 代表氢原子或-C(R12)(R13)-OC(═O)-R14 基团；R4 和 R5 与含有它们的碳一起形成饱和烃基环或任选取代的哌啶环，或 R4 代表氢原子，R5 代表任选取代的苯基或苄基、杂芳环或被杂环取代的亚甲基；R6 代表任选取代的烃基链或任选取代的苯基或苄基；以及 R7 代表氢原子或苄基、烷基、杂芳基、烷基杂芳基、-CHMe-COR18、-CHR19-OC(═O)R20 和-CHR19-OC(═O)OR20 基团。本发明还涉及这些化合物作为医药产品的用途，特别是用于治疗疼痛，尤其是神经病理性疼痛和神经炎性疼痛，还涉及它们的合成方法以及含有它们的组合物。
• Cyclopropylamines as LSD1 inhibitors
  申请人：Incyte Corporation

  公开号：US10174030B2

  公开（公告）日：2019-01-08

  The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

  本发明涉及环丙胺衍生物，它们是治疗癌症等疾病的 LSD1 抑制剂。